Our Sponsors
We believe the bigger the challenge, the bigger the need for collaboration. At GSK we have long been committed to partnering with the world’s best minds and leading institutions and investing in our own capabilities.
Founded in 2020, AOA Dx was created to ensure that women have access to the most innovative early detection platform in their fight against cancer. More than 90% of new discoveries in medical innovation stay in research within an academic setting and are never commercialized and widely adopted to help patients. We’re here to change that.
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help lifesaving treatments reach patients faster.
Sanofi US supports specific activities or initiatives of external, independent, not-for-profit healthcare-focused organizations such as academic or medical institutions, professional or scientific associations, trade organizations and organized patient groups.
Our mission to provide transformative therapies is possible only through the partnerships we form and the investments we receive. In 2020 we closed a CHF54M Series A financing round, led by Sofinnova Partners and Polaris Partners, following a seed investment from Sofinnova Partners. In 2023 we closed a CHF103M Series B financing round, led by Forbion and Jeito Capital.
Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.
